These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 10761754

  • 1. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
    Rizzari C, Zucchetti M, Conter V, Diomede L, Bruno A, Gavazzi L, Paganini M, Sparano P, Lo Nigro L, Aricò M, Milani M, D'Incalci M.
    Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
    [Abstract] [Full Text] [Related]

  • 2. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
    Gentili D, Conter V, Rizzari C, Tschuemperlin B, Zucchetti M, Orlandoni D, D'Incalci M, Masera G.
    Ann Oncol; 1996 Sep; 7(7):725-30. PubMed ID: 8905031
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia.
    Ahlke E, Nowak-Göttl U, Schulze-Westhoff P, Werber G, Börste H, Würthwein G, Jürgens H, Boos J.
    Br J Haematol; 1997 Mar; 96(4):675-81. PubMed ID: 9074406
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J.
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [Abstract] [Full Text] [Related]

  • 10. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP, Di Cataldo A, Ragusa R, Meli C, Lo Nigro L.
    J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI.
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [Abstract] [Full Text] [Related]

  • 13. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT, Nersting J, Raja RA, Frandsen TL, Rosthøj S, Schrøder H, Albertsen BK, Nordic Society of Paediatric Haematology and Oncology (NOPHO) group.
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [Abstract] [Full Text] [Related]

  • 14. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB.
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP, Wenner K, Escherich G, Lanvers-Kaminsky C, Würthwein G, Janka-Schaub G, Boos J.
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [Abstract] [Full Text] [Related]

  • 18. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
    Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K, Carlsen NT.
    Med Pediatr Oncol; 2002 May; 38(5):310-6. PubMed ID: 11979454
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
    van der Sluis IM, de Groot-Kruseman H, Te Loo M, Tissing WJE, van den Bos C, Kaspers GJL, Bierings M, Kollen WJW, König T, Pichlmeier U, Kühnel HJ, Pieters R.
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27083. PubMed ID: 29727043
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.